It was a delight to catch up with Professor Xavier Mariette (Université Paris-Saclay and Hôpital Bicêtre, Paris, France) around the phase 2 study investigating subcutaneous belimumab and intravenous rituximab in primary Sjögren’s syndrome. The abstract ‘SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED […]